Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review

<i>ROS1</i> gene rearrangements define a distinct molecular subtype of non-small cell lung cancer (NSCLC), occurring in approximately 2% of cases and frequently associated with younger age, non-smoker status, and a high incidence of brain metastases. The discovery of ROS1 as an oncogenic driver has...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hervé Bischoff, Sébastien Gendarme, Laura Somme, Christos Chouaid, Roland Schott
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2025-11-01
Edice:	Current Oncology
Témata:	ROS1 non-small cell lung cancer tyrosine kinase inhibitor resistance mutations brain metastases targeted therapy
On-line přístup:	https://www.mdpi.com/1718-7729/32/11/626
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!